Zumiez (ZUMZ) Q3 Earnings Beat Estimates, Sales Increase Y/Y

Published on December 3, 2021

Zumiez's (ZUMZ) third-quarter fiscal 2021 results reflect gains from robust strategic efforts.

Continue reading on website
Other news

Dyne Therapeutics (DYN) Submits IND to FDA for DMD Candidate

December 3, 2021
Dyne Therapeutics (DYN) files an investigational new drug application in the United States for a clinical study on its investigational candidate DYNE-251 to address Duchenne Muscular Dystrophy.

Labor Shortages And Inflation Are Affecting Everyone – But In Different Ways Than You May Think

December 3, 2021
It’s no secret that jobs have been hard to fill and that an employee shortage is having a significant impact on the economy. Additionally, the COVID-19 pandemic has disrupted public...